|
Evaluation of an OCA2 enhancer variant as a modifier of the phenotype of BAP1-Tumor predisposition syndrome
|
1R21CA219884-01A1
|
$203,471
|
$50,868
|
ABDEL-RAHMAN, MOHAMED
|
OHIO STATE UNIVERSITY
|
|
tDCS for Increasing Exercise Adherence in Individuals with Elevated Depressive Symptoms
|
1R21CA214102-01A1
|
$185,963
|
|
ABRANTES, ANA
|
BUTLER HOSPITAL (PROVIDENCE, RI)
|
|
Aerobic Exercise for Smokers with Depressive Symptomatology
|
5R01CA173551-05
|
$509,755
|
|
ABRANTES, ANA
|
BUTLER HOSPITAL (PROVIDENCE, RI)
|
|
DEVELOPMENT OF GOGGLE SYSTEM FOR FLUORESCENCE IMAGE-GUIDED SURGERY
|
5R01CA171651-05
|
$439,171
|
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-05S1
|
$2,256,906
|
$135,414
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-05
|
$192,024
|
$38,405
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-05
|
$20,853,800
|
$1,251,228
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Plumbagin in Combination with Vemurafenib for BRAF-mutant Melanoma
|
1R03CA212798-01
|
$74,250
|
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
$4,361
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-05
|
$922,200
|
$27,666
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
(PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer
|
5R01CA185357-04
|
$398,393
|
|
AHUJA, NITA
|
JOHNS HOPKINS UNIVERSITY
|
|
ATBC Study
|
ZIA CP010195 03031
|
$738,165
|
$36,908
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-05
|
$1,223,634
|
$36,709
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-02
|
$520,564
|
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
HLTF gene silencing: a novel determinant of sensitivity to autophagy inhibition
|
5R01CA169134-05
|
$312,942
|
|
AMARAVADI, RAVI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$753,084
|
$37,654
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
Integrative analysis of lung cancer etiology and risk
|
1U19CA203654-01A1
|
$2,833,706
|
|
AMOS, CHRISTOPHER
|
DARTMOUTH COLLEGE
|
|
Novel Dual Notch/PXR Targeting for Colon Cancer Therapy
|
5R01CA182872-04
|
$688,666
|
|
ANANT, SHRIKANT
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
|
Women's Health Initiative Cancer Survivor Cohort
|
5UM1CA173642-05
|
$2,260,718
|
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Hutchinson Center as Lead Academic Participating Site (U10)
|
5U10CA180828-05
|
$605,293
|
$30,265
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Childhood Cancer Survivor Study
|
3U24CA055727-24S1
|
$120,439
|
$12,044
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Childhood Cancer Survivor Study
|
5U24CA055727-24
|
$4,218,764
|
$421,876
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Stanford Cancer Institute
|
3P30CA124435-11S1
|
$248,520
|
$4,970
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
3P30CA124435-11S2
|
$171,518
|
$3,430
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
5P30CA124435-11
|
$3,334,464
|
$66,689
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
3P30CA142543-09S1
|
$249,371
|
$7,481
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
5P30CA142543-09
|
$2,480,000
|
$74,400
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant
|
2P30CA082103-19
|
$7,954,381
|
$79,544
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S1
|
$84,000
|
$840
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S2
|
$206,488
|
$2,065
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S3
|
$257,838
|
$2,578
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
The impact of e-cigarette use on adolescent uptake and persistence of conventional smoking: Who is most vulnerable?
|
5R01CA202262-02
|
$604,039
|
|
AUDRAIN-MCGOVERN, JANET
|
UNIVERSITY OF PENNSYLVANIA
|
|
Behavioral Activation for Smoking Cessation and the Prevention of Post-Cessation Weight Gain
|
5R01CA206058-02
|
$619,045
|
|
AUDRAIN-MCGOVERN, JANET
|
UNIVERSITY OF PENNSYLVANIA
|
|
Age and Diet: Major interacting factors that drive sporadic intestinal cancer
|
5R01CA174432-05
|
$660,173
|
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Biophotonics to Couple Pancreatic with Upper GI Screening via Ultrathin Endoscopy
|
5R01CA183101-03
|
$634,023
|
|
BACKMAN, VADIM
|
NORTHWESTERN UNIVERSITY
|
|
Normal and Neoplastic Growth in the Brain
|
5P01CA096832-13
|
$2,039,886
|
|
BAKER, SUZANNE
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Interferon Activated Necroptosis as a New Therapeutic Avenue for Kidney Cancer
|
5R01CA168621-04
|
$379,725
|
$379,725
|
BALACHANDRAN, SIDDHARTH
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Interferon Activated Necroptosis as a New Therapeutic Avenue for Kidney Cancer
|
5R01CA168621-05
|
$379,725
|
$379,725
|
BALACHANDRAN, SIDDHARTH
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
c-Met-induced Renalase: a novel therapeutic target for renal cancer
|
1R03CA219731-01A1
|
$88,500
|
$88,500
|
BALAN, MURUGABASKAR
|
BOSTON CHILDREN'S HOSPITAL
|
|
7T Neurosurgical Mapping Protocol for Endoscopic Resection of Skull Base Tumors
|
5R01CA202911-02
|
$387,731
|
|
BALCHANDANI, PRITI
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Dusp4 in breast cancer: tumor suppressor biology and therapeutic strategies
|
5R00CA181491-04
|
$250,586
|
|
BALKO, JUSTIN
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Functional Significance of CD133 in Pancreatic Cancer
|
5R01CA184274-04
|
$318,513
|
|
BANERJEE, SULAGNA
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
A Glycopeptide from Interstitial Cystitis Patients as a Novel Anticancer Lead
|
ZIA BC 011232
|
$314,516
|
$31,452
|
Barchi, Joseph
|
CCR (NCI)
|
|
Anatomic Pathology Residency Program
|
ZIE BC 011384
|
$1,537,925
|
$76,896
|
Barr, Frederic
|
CCR (NCI)
|
|
Fundamental subcortical mechanisms of affective processing
|
5U01CA193632-02
|
$471,734
|
|
BARRETT, LISA
|
NORTHEASTERN UNIVERSITY
|
|
MD Anderson Cancer Center EDRN- CVC for Early Detection of Ovarian Cancer
|
5U01CA200462-02
|
$889,216
|
|
BAST, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Dopamine as a therapeutic agent in stomach cancer
|
5R01CA169158-05
|
$319,550
|
|
BASU, SUJIT
|
OHIO STATE UNIVERSITY
|
|
Angiogenesis-targeting therapy for glioblastoma
|
5R01CA129371-10
|
$592,913
|
|
BATCHELOR, TRACY
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Regulation of RNA biogenesis and function by RNA modifications
|
ZIA BC 011766
|
$1,075,766
|
$322,730
|
Batista, Pedro
|
CCR (NCI)
|
|
MIC-1 and its functional partners in prostate cancer racial disparity
|
5U01CA185148-03
|
$312,080
|
|
BATRA, SURINDER
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
Total relevant funding to Kidney Disease for this search: $55,434,308
|